Start › Rak piersi potrójnie ujemny › Tennessee › Nashville
Badania kliniczne dla Rak piersi potrójnie ujemny w mieście Nashville, TN
28 badań dla Rak piersi potrójnie ujemny szuka uczestników w ośrodkach w mieście Nashville i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon Research Institute (SCRI), Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RekrutacjaFaza 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekrutacjaFaza 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekrutacjaBadanie obserwacyjne
- Vanderbilt University Medical Center, Nashville
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekrutacjaFaza 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekrutacjaFaza 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- i 1 więcej
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekrutacjaFaza 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekrutacjaFaza 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
RekrutacjaFaza 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekrutacjaBadanie obserwacyjne
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekrutacjaFaza 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
RekrutacjaFaza 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekrutacjaFaza 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekrutacjaFaza 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
RekrutacjaFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
RekrutacjaFaza 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
RekrutacjaFaza 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekrutacjaFaza 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekrutacja
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RekrutacjaFaza 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RekrutacjaFaza 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
RekrutacjaFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekrutacjaFaza 2
- SCRI Oncology Partners, Nashville
Badania dla Rak piersi potrójnie ujemny w innych miastach
- Houston, TX42 badań
- New York City, NY31 badań
- Los Angeles, CA27 badań
- Boston, MA26 badań
- San Antonio, TX23 badań
- St. Louis, MO21 badań
- Arlington, VA20 badań
- Atlanta, GA20 badań
- Dallas, TX18 badań
- Chicago, IL16 badań
- Columbus, OH16 badań
- Grand Rapids, MI15 badań
Inne badania w mieście Nashville
- Niedrobnokomórkowy rak płuca97 badań
- Rak piersi81 badań
- Nowotwór przerzutowy70 badań
- Rak jelita grubego i odbytnicy69 badań
- Nowotwory (wszystkie typy)65 badań
- Rak jajnika49 badań
- Rak prostaty43 badań
- Rak płuc40 badań
- Rak płaskonabłonkowy głowy i szyi39 badań
- Rak trzustki39 badań
- Rak endometrium38 badań
- Czerniak33 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.